The NCBiotech Bio Defense program expands the life science base of North Carolina’s $38 billion defense economy.
Our Bio Defense outreach goes far beyond concerns over bioterrorism. NCBiotech and partners -- North Carolina’s small companies, researchers and military representatives -- are thinking more broadly. We work to provide vaccines for soldiers, to protect the food supply, and to find how best to deploy novel technologies that will protect our soldiers and heal those who sustain wounds in battle.
Information on North Carolina's Bio Defense companies in North Carolina can be found in the NCBiotech Company Directory.
Given the size and significance of the federal investments in NC, NCBiotech and partners are working to bring the state’s innovative, life science technological expertise to bear to address critical challenges faced by the military and national security agencies. Developing strategies to better align the state’s well-recognized life science strengths with the Department of Defense (DoD) and national security strategic priorities will enable our state to be a critical solution provider on challenging problems while also increasing defense funding to support North Carolina researchers and companies.
Some of these NCBiotech-led activities include:
Providing support for university-based researchers and small businesses that have a technology that addresses a need in the Bio Defense arena and educate and support their efforts in seeking DoD or homeland security relationships and funding
Promoting and representing North Carolina at targeted military and federal Bio Defense conferences throughout the United States and promote our state's life science capabilities
Hosting or sponsoring conferences where military, government, academic and industry experts can network and collaborate
Connecting military, industry and academia partners to promote North Carolina’s Bio Defense capabilities at the state and federal level
For additional information, please see our Bio Defense Initiative one-pager.
Biomedical Advanced Research & Development Authority (BARDA)
For future BARDA DRIVe opportunities, sign up for the listserv.
If you or your company are developing a medical countermeasure or platform technology to combat chemical, biological, radiological, or nuclear threats, pandemic influenza or other emerging infectious diseases, you can get insights and strategic advice from HHS/ASPR Biomedical Advanced Research and Development Authority (BARDA) at a TechWatch meeting.
BARDA TechWatch meetings are your chance to introduce your proposed solution that may meet one or more of BARDA’s current priorities, and are the beginning of an important dialogue.
TechWatch meetings can be a good way in which to also get insights from other professionals from other governmental agencies with related portfolios. They can take several weeks to a couple of months to schedule so take that into consideration in your planning.
BARDA DRIVe Industry Day 2018 Presentations
BARDA remains committed to engaging industry and government partners to fulfill their mission, saving lives and protecting Americans through the research and development of medical countermeasures against serious health security threats.
The theme of BARDA Industry Day 2018 held October 29-30, 2018 in Washington, DC was "Driving Innovation." Copies of the presentations are now available online for review.
Presentations from the DRIVe Session on October 30 at 1:00 p.m. are also available below.
View the Latest Updates From BARDA
BARDA Division of Research, Innovation and Ventures (DRIVe)
BARDA is pleased to announce the expansion of its market research effort by issuing a Request for Information (RFI) in order to collect feedback on the draft solicitation document. BARDA Ventures is a key component of BARDA’s Medical Countermeasure Innovation Partnership (MCIP) under the 21st Century Cures Act.
BARDA Ventures, through a third-party non-profit, will provide dilutive investment into promising health security products and technologies to enhance national health security preparedness and response. The MCIP initiative is a key priority of ASPR and BARDA, helping to ensure that we fulfil our mission to save lives and protect Americans from 21st century health security threats. BARDA Division of Research Innovation and Ventures (DRIVe) seeks to partner with a third party entity (Ventures Partner) that will address gaps in preparedness and areas within the continuum of response which require innovative and entrepreneurial approaches that would otherwise not be considered under traditional medical countermeasure (“MCM”).
For all those interested parties – BARDA wants to hear from you! We thank those who enthusiastically provided feedback to our earlier RFI and look forward to a similar level of excitement in providing feedback to this draft solicitation. Your participation is invaluable in helping shape the final solicitation. Interested parties must respond to the RFI by November 18, 2019, 09:00am ET.
The Assistant Secretary for Preparedness and Response (ASPR) is soliciting proposals for revolutionary advancements in health security products, technologies and innovations, specifically to invigorate operations, response, recovery and medical countermeasure development, deployment and distribution activities. ASPR is seeking innovative proposals to investigate approaches that enable revolutionary advances in science, technologies, or systems. Specifically excluded are basic science, research, development, prototype and process development, data science, clinical studies, and other activities that primarily result in evolutionary improvements to the existing state of the art. ASPR is seeking approaches that are outside the mainstream, challenge assumptions, and have the potential to radically change established practice, lead to extraordinary outcomes, and create entirely new fields and commercial market disruptions with wide-ranging impact that will protect Americans from 21st Century Health Threats.
ASPR Next Areas of Interest
AOI-1: Priority Medicines on Demand
Development of transformational devices for end-to-end pharmaceutical, vaccine and/or biologics production in small-scale, modular, continuous manufacturing platforms. ASPR is also interested in developing technologies that can transform drinking water to water for sterile injection, complete with physiological additives suitable for infusion, for production at point-of-delivery.
AOI-2: Dialysis Care in Disaster Settings
Development of next-generation, portable technologies for hemodialysis in disaster settings.
AOI-3: Medical Countermeasure Deployment and Dispensing
Development of capabilities to ensure rapid deployment and dispensing of medical countermeasures or other materials to emergency response locations. This is inclusive of, but not limited to, alternate delivery methods and dispensing solutions and the development of alternative delivery platforms for pharmaceutical, vaccine and biologic administration.
AOI-4: Real-Time Healthcare System Capacity Reporting
Develop capabilities that enable secure, confidential and controlled means to track healthcare provider capacity to respond to disasters in a dynamic and timely fashion.
AOI-5: Disaster Response and Recovery Intelligence
Develop capabilities that bring together deep learning, Artificial Intelligence and Machine Learning applications to forecast disaster impacts and automate replenishment of supplies during disasters.
AOI-6: Advanced Medical Interventions
Develop capabilities to address advanced health security vulnerabilities, establish trusted data platforms to secure health-related information and investigate linkages between clinical manifestation of disease and multi-omic indicators within dedicated US-based facilities to open new pipelines for medical countermeasure discovery
AOI-7: Telehealth Applications for Response and Recovery
Establish telehealth services for medical professionals and para-professionals to better assist state, local, tribal and territorial health systems during disaster response and recovery. These teams of medical professionals and para-professionals include advanced clinicians (nurse practitioners/physician assistants), medical officers, registered nurses, respiratory therapists, paramedics, pharmacists, safety specialists, logistical specialists, information technologists, communication and administrative specialists.
AOI-8: Health Security Innovation
This Area of Interest seeks revolutionary research ideas for topics not being addressed by ongoing ASPR programs or other published solicitations.
Office of the Assistant Secretary for Preparedness & Response (ASPR)
Department of Health and Human Services
330 Independence Ave. SW
Washington, District of Columbia 20201
UPDATE: SUBMISSIONS CLOSED ON MAY 28TH. Per an announcement on FedBizOpps, abstract acceptance is temporarily on hold due to a lack of available funding.
Apply now! DRIVe's new EZ-BAA application is streamlined, fast and user-friendly.
The North Carolina Biotechnology Center is pleased to announce the Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation and Ventures (DRIVe) simplified application process, called the EZ BAA, is now open for business. Medical product developers, research teams, and companies offering disruptive solutions to health security threats are invited to submit abstracts beginning today using this simplified EZ BAA process.
BARDA is looking for the most innovative products and technologies to protect Americans from the most serious systemic, natural and intentional health security threats. Our goal is to build a portfolio of products representing disruptive innovative approaches that will transform health security.
Applications accepted through this streamlined process must offer transformative innovation, products and technologies to protect Americans from health security threats. This application process is a business-friendly simple abstract.
In-scope priority areas include: products and solutions to reduce illness and death from sepsis as part of DRIVe’s Solving Sepsis initiative; technologies and processes to identify infections and exposures to biological and other health threats, as outlined in the Early Notification to Act, Control, and Treat (ENACT) initiative; and tools and techniques to mitigate the damages and loss of life associated with catastrophic events.
Applying is simple:
- Download the application form from the website.
- Submit a technical abstract no longer than 2,000 words.
- Include a cost proposal of an additional 2,000 words or less.
- Proposed costs should not exceed $749,000.
What happens next:
- Once submitted, DRIVe’s experts will review the application to ensure it is within scope and meets DRIVe criteria.
- As the applicant, you’ll be notified of the review results within 30 days of your submission.
Learn more about the DRIVe EZ-BAA review criteria.
For more information, visit the DRIVe website.
Have questions? Looking for more information? Contact DRIVeContracting@hhs.gov
Emil Runge, Program Manager
Mobile: (404) 668-2136
First Flight Health Security Accelerator
2 Davis Drive, Research Triangle Park, NC
Combat Antibiotic Resistant Bacteria (CARB-X)
Application for CARB-X Funding Round 4 is now open:
- Direct-acting small molecule antibiotics: Funding Round 4 will be open for Expressions of Interest November 12 through November 19, 2019, 5 PM ET. The scope of Round 4 is restricted to new classes of antibiotics and/or new targets for therapeutics.
You can find all the information you need at https://carb-x.org/apply/. Please review the information in the sections under the Apply tab.
Please read the scope of each round carefully at https://carb-x.org/apply/what-carb-x-funds/, and note the timing that is relevant to your project.
NIH National Institute of General Medical Sciences
The National Institute of General Medical Sciences (NIGMS) would like to make you aware of some recent changes in the area of scientific interest related to its portfolio of sepsis research support. These changes are in response to recommendations from a NIGMS advisory council working group on sepsis.
NIGMS will be making a concerted effort to prioritize clinical research studies that utilize data and materials obtained from septic patients. Specific topics of research interest are outlined in NOT GM 19-054.
NIGMS will place added emphasis on:
- Research that is patient-based, or utilizes clinical information from humans who develop the condition of sepsis;
- Research which capitalizes on computational models and informatics, including machine learning and AI;
- Early stage research and development projects through the NIH SBIR/STTR program to create commercializable tools or technologies for sepsis research, detection, or therapy
NIGMS also plans to coordinate with other NIH institutes and government agencies to enable efficient clinical testing of new diagnostics and treatments for sepsis.
NIGMS is currently requesting information on Strategies to Support Acquisition and Use of Biospecimens for Research on Sepsis in Humans through NOT GM 19-057 and will appreciate your expert input on our RFI topics!
Please note that the deadline for responses is November 15, 2019.
United States Army Medical and Materiel Command (USAMRMC)
The United States Army Medical and Materiel Command's (USAMRMC) mission is to provide solutions to medical problems of importance to the American Service member at home and abroad, as well as to the general public at large. Extramural research and development programs play a vital role in the fulfillment of the objectives established by the USAMRMC.
The FY18-FY22 USAMRMC Broad Agency Announcement (BAA) is intended to solicit extramural research and development ideas. Research and development funded through the BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge.
Read more information.